Search Here

Zurzuvae, the new FDA-approved oral pill for postpartum depression or PPD, is now available via prescription from specialty pharmacies in the US. Biogen Inc. and Sage Therapeutics Inc. confirmed its availability in the market, but being priced at $15,900 per course before insurance has raised concerns about its accessibility. 

This treatment involves taking two 25-milligram capsules daily for 14 days and has shown rapid efficacy in reducing PPD symptoms within three days, lasting up to 45 days in trials. To address financial barriers, Biogen and Sage launched "Zurzuvae For You," providing aid and free medication to eligible patients.

Possible side effects of Zurzuvae

In a press release, Biogen and Sage note that Zurzuvae may have side effects, notably a reduced capacity to engage in activities like driving due to decreased awareness and alertness. Other side effects include sleepiness, dizziness, common cold, diarrhea, fatigue, weakness and urinary tract infections.

Individuals taking Zurzuvae may also experience impaired walking abilities, elevating the risk of falls during treatment. Combining Zurzuvae with alcohol, CNS depressants, or opioids can make these symptoms worse, potentially affecting breathing.

Other safety information

Before commencing Zurzuvae, individuals must disclose their medical history, including alcohol consumption, prior substance abuse, liver or kidney complications, pregnancy, or breastfeeding plans. Those capable of pregnancy should employ effective contraception throughout the treatment and notify their healthcare provider immediately if pregnancy occurs. 

A registry also exists for pregnant individuals exposed to Zurzuvae to monitor their health and baby. Interactions between Zurzuvae and various medications can result in severe side effects, underscoring the importance of informing healthcare providers about all medications, including over-the-counter drugs and supplements.

While taking Zurzuvae, individuals should refrain from driving, operating machinery, or undertaking hazardous activities for at least 12 hours post-dose due to potential drowsiness and dizziness. Additionally, vigilance for increased suicidal thoughts or actions is crucial, especially among individuals under 24 years old. Monitoring mood changes, attending follow-up appointments, and promptly reporting any concerning symptoms to healthcare providers are emphasized.